报价延迟最少15分钟:2024/06/02 06:00 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.44 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.23/0.40
|
|
企业价值
47.06B
|
| 资产负债 |
|
每股账面净值
4.64
|
| 现金流量 |
|
现金流量率
0.07
|
| 损益表 |
|
收益
10.86B
|
|
每股收益
3.15
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2024/06/02 06:00 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of salesfrom global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition. |